Home - Products - Angiogenesis - PDE - Verofylline

Verofylline

CAS No. 66172-75-6

Verofylline( —— )

Catalog No. M34733 CAS No. 66172-75-6

Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	333	In Stock
10MG	504	In Stock
25MG	816	In Stock
50MG	1097	In Stock
100MG	1479	In Stock
200MG	Get Quote	In Stock
500MG	2967	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Verofylline
Note

Research use only, not for human use.
Brief Description

Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.
Description

Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

PDE
Recptor

PDE
Research Area

——
Indication

——

Chemical Information

CAS Number

66172-75-6
Formula Weight

250.3
Molecular Formula

C12H18N4O2
Purity

>98% (HPLC)
Solubility

——
SMILES

C(C(CC)C)N1C2=C(C(=O)N(C)C1=O)NC(C)=N2
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

CRT0273750

CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.
LJI308

LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
Darutigenol

Darutigenol has obvious antithrombotic effect, its mechanism may be related to inhibition of platelet aggregation and adhesion.

Sign In Join Free